RESUMEN
We conducted a clinical study of MTX-HOPE (day 1, methotrexate 20 mg per os (po); day 2, hydrocortisone 100 mg intravenous (iv), vincristine 1 mg iv; day 3,4 sobuzoxane 400 mg po; etoposide 25 mg po, repeating every 2 or 3 weeks) in 14 relapsed or refractory patients with non-Hodgkin's lymphoma. Ten responders were obtained 5 CR and 5 PR), and heavily treated patients were included in the responders. The median duration of over all survival which was estimated with Kaplan-Meier curve was 11.1 months (range, 2-18+ months), and the median duration of response was 6.9 months (range, 0.8+ -16.4+ months). Out of the 14 patients,eleven were treated with this regimen in an outpatient setting. Grade 4 neutropenia and thrombocytopenia were observed in 4 and 2 patients,and grade 3 GPT-elevation and stomatitis in two and one, respectively. This newly developed MTX-HOPE therapy may be a promising treatment option for such patients as are intolerable for high-dose chemotherapies with PBSC rescue or wish for outpatient therapy.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Linfoma no Hodgkin/tratamiento farmacológico , Terapia Recuperativa , Adulto , Anciano , Anciano de 80 o más Años , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Etopósido/administración & dosificación , Femenino , Humanos , Hidrocortisona/administración & dosificación , Linfoma Folicular/tratamiento farmacológico , Linfoma Folicular/mortalidad , Linfoma de Células B Grandes Difuso/tratamiento farmacológico , Linfoma de Células B Grandes Difuso/mortalidad , Linfoma no Hodgkin/mortalidad , Masculino , Metotrexato/administración & dosificación , Persona de Mediana Edad , Neutropenia/inducido químicamente , Piperazinas/administración & dosificación , Tasa de Supervivencia , Trombocitopenia/inducido químicamente , Vincristina/administración & dosificaciónRESUMEN
The basic concept for a technique that facilitates the adjustment of a hearing aid by a person of normal hearing is proposed. The technique involves processing using an amplitude-bandwidth expansion method to expand the hearing-aid output to fit to the user's hearing requirements and loudness recruitment. The expansion is a reversal of the cochlear compression model. As the expansion method introduces distortion of the waveform and a reduction of the expansion rate, the support technique presented here includes solutions to these problems. The difference between the original speech signal and the expanded output generated from the compressed output of the original signal is virtually inaudible. This technique, which effectively simulates a patient's hearing characteristics in order to allow an audiologist to set up a patient's hearing aid, is worth further investigation.